Trial Profile

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2020 Results updated safety and efficacy profile after long-term follow-up,presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results published in the Innovent Biologics Media Release.
31 May 2020 According to an Innovent Biologics media release, the company and Eli Lilly and Company jointly announced the results from this study at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com